Clinical Trial Update: A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients [Phase 1]

View source ↗

Summary

This entry reports a completed Phase 1b/2 trial evaluating ADG116 alone and in combination with anti-PD-1 or anti-CD137 antibodies in patients with solid tumors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ADG116 (ADG116)
• Anti-PD-1 antibody
• anti-CD137 antibody

Snippet

Sponsor: Adagene Inc | Conditions: Advanced/Metastatic Solid Tumors | Phase 1 | Status: COMPLETED